THE NCCN FOUNDATION awarded its fifth series of Young Investigator Awards to six oncology researchers from NCCN Member Institutions.
The awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care, beginning in July. The studies will be managed and overseen by the NCCN Oncology Research Program.
The awards were made possible through support from AbbVie, Amgen, Genentech, Gilead, Merck, Millennium, Pfizer and Sigma-Tau.
The award recipients and their studies are:
James Blachly, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, for “Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status.”
Roisin Connolly, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, for “Harnessing the Immune System to Treat Breast Cancer: Novel Mechanisms of Resistance and Treatment Strategies.”
Areej El-Jawahri, of Massachusetts General Hospital Cancer Center, for “A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors.”
Douglas Johnson, of Vanderbilt-Ingram Cancer Center, for “Survivorship in Patients Receiving Immune Checkpoint Inhibitors.”
Todd Morgan, of the University of Michigan Comprehensive Cancer Center, for “Tissue-Based Genomics for Risk Stratification in Localized Renal Cell Carcinoma.”
Alpa Nick, of MD Anderson Cancer Center, for “Matched Pair Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination with Chemotherapy in Frontline Ovarian Cancer.”
